Bayer and Arvinas collaborate to develop the next generation of precision agriculture active ingredients

October 28, 2019 | Case Study

The $100 million endeavor and joint venture (JV) will explore novel modes of action to address food security issues associated with the control of crop pests and weeds. The JV leverages proteolysis-targeting chimeras (PROTACs), which exploit cellular defense mechanisms (e.g., ubiquitination) to degrade/recycle proteins in a targeted fashion. Accomplishing this goal requires three components: a ligand that binds ubiquitin E3 ligase, a ligand that binds to the protein target, and a linker component binding the two ligands. Arvinas' PROTAC chemistry reached human dose escalation in 2019 to treat specific instances of prostate and breast cancer. While undruggable targets lead the way in human health, applications for ag biotech are wider.

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978